Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir:A harmacogenetic study

Clinical Infectious Diseases

Volumn 48, Issue 11, 2009, Pages

  Rodríguez Nóvoa, Sonia ^a   Labarga, Pablo ^a   Soriano, Vincent ^a   Egan, Deirdre ^c   Albalater, Marta ^b   Morello, Judit ^a   Cuenca, Lorena ^a   González Pardo, Gema ^a   Khoo, Saye ^c   Back, David ^c   Owen, Andrew ^c  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER C2; ABC TRANSPORTER C4; AMINO ACID; ANTIRETROVIRUS AGENT; BETA 2 MICROGLOBULIN; CARRIER PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; PHOSPHATE; PROTEIN SLC22A11; PROTEIN SLC22A6; TENOFOVIR; UNCLASSIFIED DRUG; URIC ACID; ABCB1 PROTEIN, HUMAN; ABCC4 PROTEIN, HUMAN; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DRUG DERIVATIVE; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 2; ORGANIC ANION TRANSPORTER; PHOSPHONIC ACID DERIVATIVE; SLC22A11 PROTEIN, HUMAN;

ABCB1 GENE; ABCC2 GENE; ABCC4 GENE; ADULT; AMINOACIDURIA; ARTICLE; BETA 2 MICROGLOBULIN URINE LEVEL; BODY WEIGHT; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG CLEARANCE; FEMALE; FIRST TRIMESTER PREGNANCY; GENE; GENETIC PREDISPOSITION; GENOTYPE; GLUCOSURIA; GROUPS BY AGE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOMOZYGOSITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PHARMACOGENETICS; PHOSPHATE URINE LEVEL; PREDICTOR VARIABLE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SLC22A11 GENE; SLC22A6 GENE; TUBULAR DYSFUNCTION; URIC ACID URINE LEVEL; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETICS; HOMOZYGOTE; KIDNEY FAILURE; KIDNEY TUBULE; MOLECULAR GENETICS;

ADENINE; ADULT; ANTI-HIV AGENTS; CARRIER PROTEINS; FEMALE; GENE FREQUENCY; HIV INFECTIONS; HOMOZYGOTE; HUMANS; KIDNEY FAILURE; KIDNEY TUBULES; MALE; MOLECULAR SEQUENCE DATA; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; P-GLYCOPROTEIN; PHOSPHONIC ACIDS; POLYMORPHISM, GENETIC;

EID: 66949119640     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/598507     Document Type: Article

References (29)

1. Nelson M, Katlama C, Montaner J, et al. The safety of tenofovir di-soproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS 2007;21:1273-81.
2. Coca S, Perazella M. Acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity. Am J Med Sci 2002; 324: 342-4.
3. Rifkin B, Perazella M. Tenofovir-associated nephrotoxicity: Fanconi syndrome and renal failure. Am J Med 2004; 117:282-4.
4. Mauss S, Berger F, Schmutz G. Antiretroviral therapy with tenofovir is associated with mild renal dysfunction. AIDS 2005; 19:93-5.
5. Karras A, Lafaurie M, Furco A, et al. Tenofovir-related nephrotoxicity in HIV-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis 2003;36:1070-3.
6. Barrios A, Garcia-Benayas T, Gonzalez-Lahoz J, Soriano V. Tenofovir-related nephrotoxicity in HIV-infected patients. AIDS 2004; 18:960-3.
7. Peyriere H, Reynes J, Rouanet I, et al. Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J Acquir Immune Defic Syndr 2004; 35:269-73.
8. Verhelst D, Monge M, Meynard JL, et al. Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis 2002; 40:1331-3.
9. RayAS, Cihlar T, Robinson KL, et al. Mechanism ofactiverenaltubular efflux of tenofovir. Antimicrob Agents Chemother 2006; 50:3297-304.
10. Cihlar T, Ho E, Lin D, Mulato A. Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs. Nucleosides Nucleotides Nucleic Acids 2001; 20:641-8.
11. Robertson E, Rankin G. Human renal organic anion transporters: characteristics and contributions to drug and drug metabolite excretion. Pharmacol Ther 2006;109:399-412.
12. van Aubel R, Smeets P, van den Heuvel P, Russel F. Human organic anion transporter MRP4 (ABCC4) is an efflux pump for the purine end metabolite urate with multiple allosteric substrate binding sites. Am J Physiol Renal Physiol 2005; 288:F327-33.
13. Vormfelde S, Schirmer M, Hagos Y, et al. Torsemide renal clearance and genetic variation in luminal and basolateral organic anion transporters. Br J Clin Pharmacol 2006; 62:323-35.
14. Mallants R, Van Oosterwyck K, Van Vaeck L, Mols R, De Clercq E, Augustijins P. Multidrug resistance-associated protein 2 (MRP2) affects hepatobiliary elimination but not the intestinal disposition oftenofovir disoproxil fumarate and its metabolites. Xenobiotica 2005; 35:1055-66.
15. Miller D. Nucleoside phosphonate interactions with multiple organic anion transporters in renal proximal tubule. J Pharmacol Exp Ther 2001; 299:567-74.
16. Imaoka T, Kusuhara H, Adachi M, Schuetz J, Takeuchi K, Sugiyama Y. Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs ad-efovir and tenofovir. Mol Pharmacol 2007; 71:619-27.
17. van Aubel R, Smeets P, Peters J, Bindels R, Russel F. The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. J Am Soc Nephrol 2002; 13:595-603.
18. Izzedine H, Launay-Vacher V, Deray G. Antiviral drug-induced ne-phrotoxicity. Am J Kidney Dis 2005; 45:804-17.
19. Kiser J, Carten M, Aquilante C, et al. The effect of lopinavir/ritonavir on the renal clearance oftenofovir in HIV-infected patients. Clin Pharmacol Ther 2008; 83:265-72.
20. Izzedine H, Hulot J, Villard E, et al. Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy. J Infect Dis 2006; 194:1481-91.
21. Bleasby K, Hall L, Perry J, Mohrenweiser H, Pritchard J. Functional consequences of single nucleotide polymorphisms in the human or-ganic anion transporter hOAT1 (SLC22A6). J Pharmacol Exp Ther 2005;314:923-31.
22. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation ofone allele with P-glycoprotein expression andactivity in vivo. Proc Natl Acad Sci USA 2000; 97:3473-8.
23. Horinouchi M, Sakaeda T, Nakamura T, et al. Significant genetic linkage of MDR1 polymorphisms at positions 3435 and 2677: functional relevance to pharmacokinetics of digoxin. Pharm Res 2002; 19:1581-5.
24. Kurata Y, Leiri I, Kimura M, et al. Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin Pharmacol Ther 2002; 72:209-19.
25. Stephens M, Smith N, Donnelly P. A new statistical method for hap-lotype reconstruction from population data. Am J Hum Genet 2001 ;68:978-89.
26. Stephens M, Donnelly P. A comparison of Bayesian methods for hap-lotype reconstruction from population genotype data. Am J Hum Genet 2003; 73:1162-9.
27. Izzedine H, Hulot JS, Vittecoq D, et al. Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients: data from a double-blind randomized active-controlled multicentre study. Nephrol Dial Transplant 2005; 20:743-6.
28. Kiser J, Aquilante C, Anderson P, King T, Carten M, Fletcher C. Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients. J Acquir Immune Defic Syndr 2008; 47:298-303.
29. Jullien V, Treluyer JM, Rey E, et al. Population pharmacokinetics of tenofovir in HIV-infected patients taking highly active antiretroviral therapy. Antimicrob Agents Chemother 2005; 49:3361-6.